JP2023536653A5 - - Google Patents

Info

Publication number
JP2023536653A5
JP2023536653A5 JP2023507863A JP2023507863A JP2023536653A5 JP 2023536653 A5 JP2023536653 A5 JP 2023536653A5 JP 2023507863 A JP2023507863 A JP 2023507863A JP 2023507863 A JP2023507863 A JP 2023507863A JP 2023536653 A5 JP2023536653 A5 JP 2023536653A5
Authority
JP
Japan
Prior art keywords
binding molecule
molecule according
sdab
viral vector
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023507863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536653A (ja
JP7803927B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/044575 external-priority patent/WO2022031869A2/en
Publication of JP2023536653A publication Critical patent/JP2023536653A/ja
Publication of JP2023536653A5 publication Critical patent/JP2023536653A5/ja
Priority to JP2026001871A priority Critical patent/JP2026063000A/ja
Application granted granted Critical
Publication of JP7803927B2 publication Critical patent/JP7803927B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023507863A 2020-08-05 2021-08-04 Gp130結合分子および使用方法 Active JP7803927B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026001871A JP2026063000A (ja) 2020-08-05 2026-01-08 Gp130結合分子および使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063061562P 2020-08-05 2020-08-05
US63/061,562 2020-08-05
US202063078745P 2020-09-15 2020-09-15
US63/078,745 2020-09-15
US202163135884P 2021-01-11 2021-01-11
US63/135,884 2021-01-11
PCT/US2021/044575 WO2022031869A2 (en) 2020-08-05 2021-08-04 Gp130 binding molecules and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026001871A Division JP2026063000A (ja) 2020-08-05 2026-01-08 Gp130結合分子および使用方法

Publications (3)

Publication Number Publication Date
JP2023536653A JP2023536653A (ja) 2023-08-28
JP2023536653A5 true JP2023536653A5 (cg-RX-API-DMAC7.html) 2024-07-26
JP7803927B2 JP7803927B2 (ja) 2026-01-21

Family

ID=92301999

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023507863A Active JP7803927B2 (ja) 2020-08-05 2021-08-04 Gp130結合分子および使用方法
JP2026001871A Pending JP2026063000A (ja) 2020-08-05 2026-01-08 Gp130結合分子および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026001871A Pending JP2026063000A (ja) 2020-08-05 2026-01-08 Gp130結合分子および使用方法

Country Status (10)

Country Link
US (2) US12448457B2 (cg-RX-API-DMAC7.html)
EP (1) EP4192862A4 (cg-RX-API-DMAC7.html)
JP (2) JP7803927B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230061391A (cg-RX-API-DMAC7.html)
CN (1) CN117043188A (cg-RX-API-DMAC7.html)
AU (1) AU2021320226A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001723A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190459A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023001491A (cg-RX-API-DMAC7.html)
WO (1) WO2022031869A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116284449B (zh) * 2023-02-27 2024-11-19 深圳市先康达生命科学有限公司 增强型TGF-βR嵌合受体及其应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198919B1 (en) 1983-04-25 2007-04-03 Genentech, Inc. Use of alpha factor sequences in yeast expression systems
US4569794A (en) 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5439829A (en) 1991-01-30 1995-08-08 Eli Lilly And Company Immobilization of biologically active molecules by changing the Oxidation state of a chelated transition metal ion
CA2113990A1 (en) 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5320663A (en) 1992-07-02 1994-06-14 E. I. Du Pont De Nemours And Company Method of obtaining lead and organolead from contaminated media using metal accumulating plants
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
JP2008501706A (ja) 2004-06-04 2008-01-24 ジェネンテック・インコーポレーテッド 疾患の治療方法
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
DE602006009834D1 (de) 2005-09-01 2009-11-26 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
DK2046809T3 (en) 2006-07-19 2017-03-13 Univ Pennsylvania WSX-1 / IL-27 AS A TARGET OBJECTIVE FOR ANTI-INFLAMMATORY REACTIONS
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US20110311550A1 (en) * 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
WO2012097238A2 (en) 2011-01-14 2012-07-19 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
EP2729488A4 (en) 2011-07-06 2015-01-14 Medimmune Llc PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013059299A1 (en) 2011-10-17 2013-04-25 The Uab Research Foundation Antibodies for interferon subtypes and interferon/interferon receptor ternary complex and uses thereof
WO2013180200A1 (ja) * 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
JP6693872B2 (ja) 2013-07-25 2020-05-13 シトムクス セラピューティクス,インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
US20160251440A1 (en) 2013-09-26 2016-09-01 Ablynx N.V. Bispecific nanobodies
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
IL300029A (en) 2014-05-16 2023-03-01 Baylor Res Institute Methods and preparations for the treatment of autoimmune and inflammatory conditions
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
HRP20191800T1 (hr) 2015-05-13 2019-12-27 Ablynx N.V. Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
CN107400166A (zh) 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
CN110312736B (zh) * 2017-01-23 2023-05-09 苏州康宁杰瑞生物科技有限公司 Pd-l1结合多肽或化合物
SG11201908929VA (en) 2017-03-31 2019-10-30 Univ Leland Stanford Junior Synthekine compositions and methods of use
EP3634465A4 (en) 2017-05-25 2021-01-20 The Broad Institute, Inc. LYMPHOCYTE ANTIGEN CD5 SIMILAR (CD5L) MONOMER, HOMODIMER AND INTERLEUKIN 12B (P40) HETERODIMER ANTAGONISTS AND METHOD OF USE THEREOF
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
SG11202005146VA (en) * 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
SG11202004158QA (en) 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag BCMA chimeric antigen receptors and their uses
WO2019242632A1 (en) 2018-06-19 2019-12-26 1§1Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
AU2019321490B2 (en) 2018-08-13 2025-09-04 Inhibrx Biosciences, Inc. Ox40-binding polypeptides and uses thereof
WO2020144164A1 (en) 2019-01-07 2020-07-16 Bactolife Aps Pathogen binding proteins
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
CN111018985B (zh) 2019-12-06 2021-06-18 南京融捷康生物科技有限公司 针对牛血清白蛋白bsa的单域抗体的应用
KR20230061392A (ko) 2020-08-05 2023-05-08 신테카인, 인크. 수용체 쌍형성과 관련된 조성물 및 방법
KR102846963B1 (ko) 2020-08-05 2025-08-18 신테카인, 인크. IL27Rα 결합 분자 및 사용 방법
EP4192502A4 (en) 2020-08-05 2024-10-09 Synthekine, Inc. Compositions and methods related to il27 receptor binding

Similar Documents

Publication Publication Date Title
JP2023536654A5 (cg-RX-API-DMAC7.html)
JP7453206B2 (ja) 改良された血清アルブミン結合剤
JP7195142B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP2023538518A5 (cg-RX-API-DMAC7.html)
EP4198055A1 (en) Antibody of il-11 and use thereof
JP2022513420A5 (cg-RX-API-DMAC7.html)
CN110121509A (zh) 中和抗tl1a单克隆抗体
TW200819464A (en) Anti-NKG2A antibodies and uses thereof
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2023516280A5 (cg-RX-API-DMAC7.html)
JP2023159169A (ja) 抗il12/il23抗体でループスを治療する安全かつ有効な方法
TWI902681B (zh) 抗cd79b抗體、其抗原結合片段及其醫藥用途
JP2023536651A5 (cg-RX-API-DMAC7.html)
JP2022502024A5 (cg-RX-API-DMAC7.html)
JP2017507131A5 (cg-RX-API-DMAC7.html)
US20250263467A1 (en) Antibody therapies for sars-cov-2 infection
JP6918005B2 (ja) 細胞内抗原に対して向けられた単一ドメイン抗体
KR102822827B1 (ko) 칸디다에 대한 항체 및 이의 용도
CN114805563B (zh) SARS-CoV-2 α、γ、δ和ο突变株骆驼源高亲和力纳米抗体
WO2024165049A1 (zh) 抗cdh6的抗体及其用途
JP2021530428A (ja) 頭頸部癌の処置
WO2025242094A1 (zh) 靶向bdca2的抗体或其抗原结合片段及其应用
CN121358774A (zh) 与nkg2a结合的抗体或抗原结合片段及其用途
TW202308649A (zh) 用於治療卵巢癌之卡鉑與靶向NaPi2b之抗體聚合物-藥物共軛體的組合療法
US20230140694A1 (en) Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies